PriceTargets.com logo

BioNTech - BNTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $136.42
  • Forecasted Upside: 42.10%
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$96.00 As of 12/4/2025 05:00 PM ET
▼ -0.73 (-0.75%)

This chart shows the closing price for BNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioNTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

Analyst Price Target is $136.42
▲ +42.10% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $136.42, with a high forecast of $171.44 and a low forecast of $110.00. The average price target represents a 42.10% upside from the last price of $96.00.

This chart shows the closing price for BNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 investment analysts is to moderate buy stock in BioNTech. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/3/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy$151.00 ➝ $151.00
11/25/2025Berenberg BankReiterated RatingBuy
11/17/2025Berenberg BankReiterated RatingBuy ➝ Buy
11/12/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy
11/10/2025HC WainwrightBoost TargetBuy ➝ Buy$136.00 ➝ $140.00
11/6/2025UBS GroupBoost TargetNeutral ➝ Neutral$115.00 ➝ $117.00
11/3/2025CowenReiterated RatingHold ➝ Hold
11/3/2025Morgan StanleyReiterated RatingOverweight ➝ Overweight$134.00
11/3/2025Jefferies Financial GroupReiterated RatingBuy
10/23/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$121.00 ➝ $120.00
10/22/2025Bank of AmericaLower TargetBuy ➝ Buy$134.00 ➝ $130.00
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/10/2025Morgan StanleyLower TargetOverweight ➝ Overweight$133.00 ➝ $131.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/22/2025JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$116.00 ➝ $121.00
9/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$136.00
8/14/2025HC WainwrightLower TargetBuy ➝ Buy$138.00 ➝ $136.00
8/5/2025Bank of AmericaBoost TargetBuy ➝ Buy$126.00 ➝ $134.00
8/5/2025Wells Fargo & CompanySet TargetOverweight ➝ Overweight$170.00 ➝ $150.00
7/16/2025Bank of AmericaLower TargetBuy ➝ Buy$127.00 ➝ $126.00
7/10/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$132.00 ➝ $133.00
6/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$138.00
6/16/2025HC WainwrightLower TargetBuy ➝ Buy$145.00 ➝ $138.00
6/5/2025HC WainwrightBoost TargetBuy ➝ Buy$134.00 ➝ $145.00
6/3/2025Truist FinancialReiterated RatingBuy ➝ Buy$151.00 ➝ $155.00
6/2/2025Leerink PartnersSet Target$112.00
5/29/2025The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$110.00
5/22/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025HC WainwrightReiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
5/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$145.00 ➝ $134.00
5/6/2025CitigroupReiterated RatingBuy ➝ Buy$145.00 ➝ $140.00
5/6/2025Morgan StanleyLower TargetOverweight ➝ Overweight$140.00 ➝ $132.00
4/1/2025HC WainwrightLower TargetBuy ➝ Buy$150.00 ➝ $145.00
3/13/2025CitigroupInitiated CoverageBuy$145.00
3/11/2025Morgan StanleyLower TargetOverweight ➝ Overweight$145.00 ➝ $139.00
3/11/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$171.44 ➝ $171.44
3/11/2025BMO Capital MarketsBoost TargetOutperform ➝ Outperform$130.00 ➝ $143.00
1/10/2025Truist FinancialInitiated CoverageBuy$172.00
12/11/2024Wells Fargo & CompanyInitiated CoverageOverweight$170.00
12/2/2024BMO Capital MarketsReiterated RatingOutperform
11/27/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$171.00 ➝ $171.44
11/26/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$124.00 ➝ $122.00
11/19/2024Berenberg BankInitiated CoverageBuy$130.00
11/19/2024Evercore ISIUpgradeIn-Line ➝ Outperform$110.00 ➝ $125.00
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$150.00 ➝ $150.00
11/14/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$171.00 ➝ $171.00
11/8/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$90.00 ➝ $137.00
11/5/2024TD CowenLower TargetHold ➝ Hold$132.00 ➝ $122.00
11/4/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$125.00 ➝ $124.00
10/21/2024TD CowenBoost TargetHold ➝ Hold$85.00 ➝ $132.00
10/7/2024HSBCBoost TargetBuy ➝ Buy$97.00 ➝ $136.00
10/7/2024HC WainwrightBoost TargetBuy ➝ Buy$113.00 ➝ $150.00
9/24/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$93.00 ➝ $145.00
9/19/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$95.00 ➝ $150.00
9/18/2024UBS GroupBoost TargetNeutral ➝ Neutral$97.00 ➝ $131.00
9/17/2024Jefferies Financial GroupUpgradeHold ➝ Buy$96.00 ➝ $150.00
9/16/2024Bank of AmericaBoost TargetBuy ➝ Buy$125.00 ➝ $150.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
9/16/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$91.00 ➝ $125.00
9/13/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$90.00 ➝ $96.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
8/15/2024JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$94.00 ➝ $91.00
8/7/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$95.00 ➝ $95.00
8/6/2024TD CowenLower TargetHold ➝ Hold$98.00 ➝ $85.00
8/2/2024Hsbc Global ResUpgradeHold ➝ Strong-Buy
8/2/2024HSBCUpgradeHold ➝ Buy
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
6/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
6/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$113.00 ➝ $113.00
5/14/2024Evercore ISIInitiated CoverageInline$100.00
5/8/2024HC WainwrightBoost TargetBuy ➝ Buy$107.00 ➝ $113.00
5/7/2024TD CowenBoost TargetHold ➝ Hold$95.00 ➝ $98.00
5/7/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$123.00 ➝ $122.00
4/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$107.00
3/27/2024UBS GroupLower TargetNeutral ➝ Neutral$110.00 ➝ $101.00
3/22/2024JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$99.00 ➝ $90.00
3/21/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$127.00 ➝ $123.00
3/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$171.00
2/28/2024The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$113.00 ➝ $100.00
2/23/2024BMO Capital MarketsInitiated CoverageOutperform$127.00
2/20/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$168.00 ➝ $171.00
1/23/2024HC WainwrightLower TargetBuy ➝ Buy$133.00 ➝ $107.00
1/5/2024OppenheimerInitiated CoverageMarket Perform
12/1/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$106.00 ➝ $99.00
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$133.00
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$180.00 ➝ $133.00
11/8/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$110.00 ➝ $111.00
10/17/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$116.00 ➝ $110.00
10/16/2023HSBCDowngradeBuy ➝ Hold$124.00 ➝ $111.00
8/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$180.00
8/10/2023HC WainwrightLower TargetBuy ➝ Buy$181.00 ➝ $180.00
8/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$119.00 ➝ $116.00
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$119.00
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$119.00
7/14/2023HSBCInitiated CoverageBuy$124.00
6/1/2023HC WainwrightLower Target$198.00 ➝ $181.00
5/23/2023HC WainwrightLower Target$210.00 ➝ $198.00
5/18/2023Deutsche Bank AktiengesellschaftLower Target$135.00 ➝ $120.00
5/17/2023Redburn PartnersUpgradeNeutral ➝ Buy$165.00 ➝ $170.00
4/10/2023JPMorgan Chase & Co.Lower TargetNeutral$142.00 ➝ $128.00
3/31/2023UBS GroupLower TargetNeutral$168.00 ➝ $153.00
3/30/2023HC WainwrightReiterated RatingBuy$210.00
3/28/2023Canaccord Genuity GroupBoost TargetBuy$191.00 ➝ $203.00
3/28/2023TD CowenLower TargetMarket Perform$145.00 ➝ $130.00
3/28/2023The Goldman Sachs GroupSet TargetNeutral$156.00 ➝ $140.00
3/28/2023Berenberg BankSet Target$260.00
3/28/2023Morgan StanleyLower TargetEqual Weight$216.00 ➝ $150.00
3/28/2023Jefferies Financial GroupSet Target$145.00
3/27/2023Bank of AmericaLower TargetBuy$239.00 ➝ $194.00
3/23/2023HC WainwrightLower TargetBuy$272.00 ➝ $210.00
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$148.00 ➝ $142.00
2/1/2023UBS GroupSet Target$168.00
1/31/2023The Goldman Sachs GroupLower TargetNeutral$177.00 ➝ $156.00
1/30/2023Berenberg BankSet Target$300.00
1/24/2023Morgan StanleyBoost TargetEqual Weight$203.00 ➝ $216.00
1/16/2023The Goldman Sachs GroupSet Target$177.00
1/11/2023JPMorgan Chase & Co.Set Target$148.00
12/15/2022Bank of AmericaUpgradeNeutral ➝ Buy$239.00
11/21/2022JPMorgan Chase & Co.Set Target$148.00
11/15/2022UBS GroupSet Target$168.00
11/8/2022Berenberg BankSet Target$312.00
11/8/2022Morgan StanleyBoost TargetEqual Weight$194.00 ➝ $203.00
11/8/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$200.00 ➝ $191.00
11/8/2022The Goldman Sachs GroupLower TargetNeutral$200.00 ➝ $177.00
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$183.00 ➝ $132.00
10/21/2022Berenberg BankSet Target$312.00
9/27/2022Berenberg BankSet Target$312.00
9/8/2022Deutsche Bank AktiengesellschaftSet Target$180.00
9/8/2022Berenberg BankSet Target$312.00
8/17/2022CowenInitiated CoverageMarket Perform$177.00
8/17/2022CowenInitiated CoverageMarket Perform
8/10/2022HC WainwrightLower TargetBuy$283.00 ➝ $272.00
8/9/2022The Goldman Sachs GroupSet Target$200.00
8/9/2022Berenberg BankSet Target$312.00
8/9/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$192.00 ➝ $200.00
7/29/2022Leerink PartnersBoost TargetOutperform$223.00 ➝ $224.00
7/15/2022Morgan StanleyLower TargetEqual Weight$195.00 ➝ $194.00
7/13/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$253.00 ➝ $223.00
7/11/2022HC WainwrightLower TargetBuy$298.00 ➝ $283.00
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$192.00
7/1/2022Deutsche Bank AktiengesellschaftSet Target$180.00
6/30/2022The Goldman Sachs GroupSet Target$209.00
6/30/2022UBS GroupSet Target$168.00
6/15/2022The Goldman Sachs GroupSet Target$206.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$255.00 ➝ $206.00
5/11/2022The Goldman Sachs GroupSet Target$255.00
5/10/2022JPMorgan Chase & Co.Set Target$183.00
5/9/2022Jefferies Financial GroupSet Target$230.00
4/12/2022HC WainwrightLower TargetBuy$339.00 ➝ $298.00
4/12/2022Morgan StanleyLower TargetEqual Weight$217.00 ➝ $197.00
4/11/2022Berenberg BankReiterated RatingBuy$350.00
4/5/2022Canaccord Genuity GroupLower TargetBuy$450.00 ➝ $300.00
4/5/2022UBS GroupLower TargetBuy ➝ Buy$450.00 ➝ $300.00
4/5/2022Berenberg BankSet Target$400.00
4/1/2022The Goldman Sachs GroupSet Target$255.00
4/1/2022Deutsche Bank AktiengesellschaftSet Target$200.00
3/31/2022JPMorgan Chase & Co.Set Target$183.00
3/30/2022Jefferies Financial GroupSet Target$230.00
3/18/2022Jefferies Financial GroupSet Target$230.00
2/23/2022HC WainwrightLower TargetBuy$366.00 ➝ $339.00
2/14/2022HC WainwrightReiterated RatingBuy$366.00
2/1/2022Morgan StanleyLower TargetEqual Weight$284.00 ➝ $217.00
2/1/2022Redburn PartnersUpgradeSell ➝ Neutral
1/19/2022HC WainwrightReiterated RatingBuy$366.00
1/18/2022Morgan StanleyLower TargetEqual Weight$294.00 ➝ $284.00
1/12/2022The Goldman Sachs GroupSet Target$299.00
1/5/2022Berenberg BankSet Target$400.00
1/4/2022HC WainwrightReiterated RatingBuy$366.00
12/22/2021UBS GroupUpgradeNeutral ➝ Buy
12/21/2021HC WainwrightBoost TargetBuy$360.00 ➝ $366.00
12/16/2021Morgan StanleyInitiated CoverageEqual Weight$294.00
12/9/2021Deutsche Bank AktiengesellschaftSet Target$225.00
12/8/2021Berenberg BankSet Target$400.00
12/8/2021Jefferies Financial GroupSet Target$230.00
12/6/2021Bank of AmericaBoost TargetNeutral ➝ Neutral$341.00 ➝ $349.00
11/29/2021Berenberg BankSet Target$400.00
11/22/2021Jefferies Financial GroupSet Target$230.00
11/10/2021HC WainwrightUpgradeNeutral ➝ Buy$242.00 ➝ $360.00
11/10/2021JPMorgan Chase & Co.Set Target$180.00
11/9/2021Jefferies Financial GroupSet Target$230.00
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00
10/7/2021Jefferies Financial GroupSet Target$230.00
10/6/2021Jefferies Financial GroupInitiated CoverageHold$230.00
10/5/2021HC WainwrightReiterated RatingHold$330.00
10/5/2021Berenberg BankSet Target$400.00
10/5/2021Leerink PartnersLower TargetMarket Perform$293.00 ➝ $268.00
10/5/2021Bryan, Garnier & CoSet Target$359.00
9/29/2021HC WainwrightReiterated RatingHold$330.00
9/29/2021The Goldman Sachs GroupSet Target$433.00
9/24/2021Bryan, Garnier & CoSet Target$451.00
9/23/2021UBS GroupSet Target$300.00
9/23/2021The Goldman Sachs GroupSet Target$433.00
9/21/2021HC WainwrightReiterated RatingHold$330.00
8/31/2021HC WainwrightReiterated RatingHold$330.00
8/27/2021UBS GroupBoost TargetNeutral$111.00 ➝ $300.00
8/13/2021Leerink PartnersBoost TargetMarket Perform$159.00 ➝ $293.00
8/11/2021HC WainwrightBoost TargetNeutral$194.00 ➝ $330.00
8/11/2021Bryan, Garnier & CoUpgradeNeutral ➝ Buy
8/8/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral
7/22/2021Leerink PartnersReiterated RatingHold
7/20/2021HC WainwrightReiterated RatingHold$194.00
7/19/2021Wolfe ResearchInitiated CoverageOutperform$248.00
7/14/2021HC WainwrightReiterated RatingHold$194.00
6/23/2021Leerink PartnersReiterated RatingHold
6/16/2021Redburn PartnersReiterated RatingNeutral ➝ Sell$146.00
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$173.00
5/17/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$135.00 ➝ $206.00
5/11/2021Leerink PartnersBoost TargetPositive ➝ Market Perform$118.00 ➝ $159.00
5/11/2021Bryan, Garnier & CoDowngradeBuy ➝ Neutral$135.00 ➝ $206.00
4/13/2021Leerink PartnersBoost TargetMarket Perform$110.00 ➝ $118.00
4/6/2021Leerink PartnersBoost TargetMarket Perform$106.00 ➝ $110.00
4/6/2021Berenberg BankSet TargetBuy$130.00
4/6/2021JPMorgan Chase & Co.Set TargetNeutral$104.00
3/31/2021JPMorgan Chase & Co.Reiterated RatingNeutral$104.00
3/31/2021Berenberg BankReiterated RatingBuy$130.00
2/4/2021Leerink PartnersBoost TargetMarket Perform$97.00 ➝ $106.00
1/11/2021Berenberg BankSet TargetBuy$126.00
12/15/2020Leerink PartnersBoost TargetMarket Perform$91.00 ➝ $97.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 27 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
5/9/2025
  • 32 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
6/8/2025
  • 14 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
7/8/2025
  • 25 very positive mentions
  • 19 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 30 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
Mentions as of
9/6/2025
  • 20 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 15 very positive mentions
  • 29 positive mentions
  • 6 negative mentions
  • 7 very negative mentions
Mentions as of
11/5/2025
  • 24 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 24 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

BioNTech logo
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Read More

Today's Range

Now: $96.00
Low: $95.59
High: $98.11

50 Day Range

MA: $102.89
Low: $95.59
High: $111.61

52 Week Range

Now: $96.00
Low: $81.20
High: $129.27

Volume

1,608,728 shs

Average Volume

1,209,268 shs

Market Capitalization

$21.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: Bank of America Corporation, Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for BNTX.

What is the current price target for BioNTech?

0 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $136.42, suggesting a possible upside of 42.1%. Canaccord Genuity Group Inc. has the highest price target set, predicting BNTX will reach $171.44 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $110.00 for BioNTech in the next year.
View the latest price targets for BNTX.

What is the current consensus analyst rating for BioNTech?

BioNTech currently has 1 sell rating, 4 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BNTX.

What other companies compete with BioNTech?

Other companies that are similar to BioNTech include argenex, Takeda Pharmaceutical, Insmed, BeOne Medicines and Teva Pharmaceutical Industries. Learn More about companies similar to BioNTech.

How do I contact BioNTech's investor relations team?

BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected]. The official website for BioNTech is www.biontech.de. Learn More about contacing BioNTech investor relations.